Table 1.
Social and demographic description.
| SpA | AS+ | uSpA+ | ReA+ | IBD | HS | |
|---|---|---|---|---|---|---|
| (n = 102) | (n = 29) | (n = 58) | (n = 15) | (n = 29) | (n = 117) | |
| Age† | 42.2 ± 15.1 | 48.4 ± 16.5 | 38.1 ± 13.3 | 37.3 ± 13.6 | 48.7 ± 13.3 | 41.2 ± 13.3 |
| Gender (male)§ | 42 (40.7) | 18 (62.1) | 35 (60.3) | 7 (46.7) | 16 (50.0) | 55 (47) |
| Weight† | 69.9 ± 12.6 | 73.9 ± 11.6 | 69.5 ± 12.1 | 63 ± 13.7 | 72.8 ± 13.6 | 67.5 ± 12.9 |
| HLA-B27§ | 40 (39.6) | 17 (60.7) | 18 (32.7) | 5 (33.3) | N/A | 5(4)∗ |
| BASFI > 4§ | 60 (60.6) | 18 (62.1) | 38 (66.0) | 8 (53.3) | N/A | N/A |
| BASDAI > 4§ | 67 (67.7) | 19 (62.1) | 41 (70.7) | 11 (73.3) | N/A | N/A |
| ESR > 20 mm3/h§ | 39 (39.4) | 17 (60.7) | 20 (34.5) | 7 (46.7) | 26.7 (23.5) | 9.9 (10.0)∗ |
| CRP > 3 mg/Dl§ | 9 (9.6) | 28 (96.6) | 53 (91.4) | 14 (93.3) | 2.05 (3.5) | 3.73 (4.8)∗ |
| IgA (mg/dL)‡ | 272 (210–372) | 251 (214–383) | 272 (197–377) | 270 (164–353) | 329 (233–442) | 274 (210–355) |
| Treatment | ||||||
| NSAIDS§ | 24 (24.5) | 5 (17.2) | 17 (31.5) | 1 (7.1) | None | N/A |
| Sulfasalazine§ | 8 (8.2) | 1 (3.4) | 6 (11.1) | 2 (7.1) | 1 (3.4) | N/A |
| Anti-TNF§ | 24 (24.5) | 9 (31.0) | 10 (18.5) | 5 (35.7) | 4 (13.7) | N/A |
| Combination with anti-TNF§ | 23 (23.5) | 8 (27.6) | 10 (18.5) | 5 (35.7) | 1 (3.4) | N/A |
| Sulfasalazine + NSAID§ | 19 (19.4) | 6 (20.7) | 11 (20.4) | 2 (14.3) | None | N/A |
| Mesalazine§ | None | None | None | None | 21 (72.4) | N/A |
§Results expressed as n (%). †Results expressed as mean ± standard deviation. ‡Results expressed as median (interquartile range). BASFI: Bath Ankylosing Spondylitis Functional Index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, Anti-TNF: antitumor necrosis factor, NSAID: nonsteroid anti-inflammatory drugs; N/A: not applied, ∗p < 0.05. +Diagnosis at the beginning of SpA diseases.